Healthy, Schizoaffective Disorder, Schizophrenia
Conditions
Keywords
Schizophrenia, Muscarinic M1 Receptor, M1 AChR, [11C]EMO, PET Scan, MRI Scan
Brief summary
This exploratory study seeks to examine M1 receptor availability in SZ patients and to relate M1 receptor availability to proximal and distal measures of cognitive performance, namely evoked ɣ oscillations in the EEG and verbal memory. Furthermore, the relationship between hippocampal \[11C\]EMO availability (BPND), evoked ɣ oscillations, verbal memory, and measures of illness severity will be explored.
Detailed description
Converging lines of evidence from postmortem studies provide strong evidence that brain muscarinic M1 receptor deficit is present in a subset of schizophrenia (SZ) patients. M1 receptors are an important target for cognitive deficits in SZ. However, until now, it has not been possible to examine the heterogeneity of SZ with respect to M1 receptor availability in vivo. The development of a novel positron emission tomography (PET) ligand, \[11C\]EMO, at Yale PET Center provides a unique opportunity to, for the first time, examine in vivo brain muscarinic M1 receptor availability in SZ and, concurrently, elucidate the relationship of M1 receptors to cognitive deficits in SZ. The investigators will compare M1 receptor availability in SZ patients and age-, gender-matched healthy controls using \[11C\]EMO and the High Resolution Research Tomograph (HRRT), a PET scanner with high sensitivity and resolution available for human brain imaging. This study will explore the relationship between: hippocampal \[11C\]EMO binding (as a measure of hippocampal M1 AChR availability), encoding-related γ power during a verbal memory task, verbal memory, gender, and serum acetylcholine level. This exploratory study will provide the necessary pilot data to conduct a larger study to fully investigate the heterogeneity of SZ with respect to M1 receptor availability.
Interventions
DRUG11C-EMO - A Novel PET Radiotracer for Muscarinic M1 Receptor
The radiotracer, \[11C\]EMO, will be administered at the beginning of each PET scan.
DEVICEPET Scan
PET scanner with high sensitivity and resolution available for human brain imaging
Sponsors
National Institute of Mental Health (NIMH)
Yale University
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE
Intervention model description
Two groups will be studied: 1.) patients diagnosed with schizophrenia or schizoaffective disorder, and 2.) age and gender-matched healthy controls. Both groups will undergo neuroimaging, cognitive assessments, etc.
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Men and women aged 18- 65 years that are physically and mentally healthy with the exception of DSM-5 schizophrenia or schizoaffective disorder diagnosis * Subjects with no metal in the body that may pose a risk during MRI scanning * No significant medical history, including head trauma and bleeding disorders
Exclusion criteria
* Men and women with a history or presence of clinically significant medical conditions * People who suffer from claustrophobia, have MRI incompatible implants, or other contraindications for MRI and PET scans
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Hippocampal M1 availability | 10 days | Measured by \[11C\]EMO availability (BPND) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| evoked ɣ oscillations | 10 days | Measured by EEG |
| verbal memory | 10 days | Measured by cognitive assessments |
Countries
United States
Outcome results
None listed